Here's What Caused Sarepta Therapeutics to Shoot 13% Higher In November

Here's What Caused Sarepta Therapeutics to Shoot 13% Higher In November

A month full of news related to the progress it's making toward helping patients with Duchenne muscular dystrophy (DMD) sparked a 12.9% rally in Sarepta Therapeutics (NASDAQ: SRPT) shares last month, according to S&P Global Market Intelligence.

DMD is a life-shortening, muscle-wasting disease caused by the limited or non-existent production of dystrophin, a protein important to muscle building. DMD is diagnosed in thousands of patients, and there are limited treatment options available.

Sarepta Therapeutics aims to change that.

Continue reading

Source: Fool.com